Log in

NASDAQ:ETON - Eton Pharmaceuticals Stock Price, Forecast & News

$7.14
-0.33 (-4.42 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$7.13
Now: $7.14
$7.50
50-Day Range
$5.97
MA: $6.79
$7.46
52-Week Range
$5.13
Now: $7.14
$10.20
Volume48,984 shs
Average Volume58,283 shs
Market Capitalization$127.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.14
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETON
CUSIPN/A
CIKN/A
Phone847-787-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.49 per share

Profitability

Net Income$-12,740,000.00

Miscellaneous

Employees15
Market Cap$127.16 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.


A Rare Upcoming Change to Bitcoin Could Yield Profits of 2,752% (Ad)


Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals Inc (NASDAQ:ETON) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. View Eton Pharmaceuticals' Earnings History.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Eton Pharmaceuticals.

What price target have analysts set for ETON?

3 Wall Street analysts have issued 12 month price targets for Eton Pharmaceuticals' stock. Their forecasts range from $13.50 to $21.00. On average, they anticipate Eton Pharmaceuticals' share price to reach $17.25 in the next year. This suggests a possible upside of 141.6% from the stock's current price. View Analyst Price Targets for Eton Pharmaceuticals.

What is the consensus analysts' recommendation for Eton Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eton Pharmaceuticals.

Has Eton Pharmaceuticals been receiving favorable news coverage?

Press coverage about ETON stock has been trending very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Eton Pharmaceuticals.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 412,700 shares, an increase of 12.9% from the December 15th total of 365,600 shares. Based on an average trading volume of 109,600 shares, the days-to-cover ratio is presently 3.8 days. Approximately 3.7% of the shares of the stock are short sold. View Eton Pharmaceuticals' Current Options Chain.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the folowing people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Centric Wealth Management (0.16%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Institutional Ownership Trends for Eton Pharmaceuticals.

Which institutional investors are buying Eton Pharmaceuticals stock?

ETON stock was bought by a variety of institutional investors in the last quarter, including Centric Wealth Management. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Insider Buying and Selling for Eton Pharmaceuticals.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $7.14.

How big of a company is Eton Pharmaceuticals?

Eton Pharmaceuticals has a market capitalization of $127.16 million. The company earns $-12,740,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.View Additional Information About Eton Pharmaceuticals.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is http://www.etonpharma.com/.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]


MarketBeat Community Rating for Eton Pharmaceuticals (NASDAQ ETON)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote "Outperform" if you believe ETON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel